Canavan disease: Clinical features and recent advances in research

Pediatrics International

Volumn 56, Issue 4, 2014, Pages 477-483

  Hoshino, Hideki ^a,b   Kubota, Masaya ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Aspartoacylase; Canavan disease; Leukodystrophy; N acetylaspartic acid; Spongy degeneration

Indexed keywords

ACETAZOLAMIDE; ACETIC ACID; ANTICONVULSIVE AGENT; ASPARTOACYLASE; LITHIUM CITRATE; N ACETYLASPARTIC ACID; TRIACETIN; TRIHEPTANOIN;

CANAVAN DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ELECTROENCEPHALOGRAPHY; EVOKED RESPONSE; GENETIC SCREENING; HUMAN; JAPANESE (PEOPLE); MISSENSE MUTATION; MOLECULAR DIAGNOSIS; NERVE CONDUCTION; NEUROIMAGING; NONHUMAN; NOSE FEEDING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEIZURE;

CANAVAN DISEASE; HUMANS;

EID: 84926022887     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/ped.12422     Document Type: Review

References (53)

1. Canavan WP. Reaction of the contents of Trichinella spiralis cysts. Science 1931; 74: 71.
2. Bertrand I, Van Bogaert L. [Demyelinizing diseases in man and animals: Remarks and conclusions]. Acta Neurol. Psychiatr. Belg. 1954; 54: 682-91.
3. Matalon R, Michals K, Sebesta D., Deanching M, Gashkoff P, Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am. J. Med. Genet. 1988; 29: 463-71.
4. Kaul R, Balamurugan K, Gao G.P., Matalon R. Canavan disease: Genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution. Genomics 1994; 21: 364-70.
5. Adachi M, Schneck L, Cara J., Volk BW. Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). A review. Hum. Pathol. 1973; 4: 331-47.
6. Moffett JR, Namboodiri AM. Preface: A brief review of N-acetylaspartate. Adv. Exp. Med. Biol. 2006; 576: vii-xiii.
7. Gascon GG, Ozand PT, Mahdi A et al. Infantile CNS spongy degeneration - 14 cases: Clinical update. Neurology 1990; 40: 1876-82.
8. Matalon RM, Michals-Matalon K. Spongy degeneration of the brain, Canavan disease: Biochemical and molecular findings. Front. Biosci. 2000; 5: D307-11.
9. Inoue Y, Kuhara T. Rapid and sensitive screening for and chemical diagnosis of Canavan disease by gas chromatography-mass spec-trometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2004; 806: 33-9.
10. Bartalini G, Margollicci M, Balestri P., Farnetani MA, Cioni M, Fois A. Biochemical diagnosis of Canavan disease. Childs Nerv. Syst. 1992; 8: 468-70.
11. Divry P, Mathieu M. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am. J. Med. Genet. 1989; 32: 550-51.
12. Hagenfeldt L, Bollgren I, Venizelos N. N-acetylaspartic aciduria due to aspartoacylase deficiency: A new aetiology of childhood leukodystrophy. J. Inherit. Metab. Dis. 1987; 10: 135-41.
13. van der Knaap MS. Canavan Disease, Magnetic Resonance of Myelination and Myelin Disorders, 3rd edn. Springer, Berlin, 2005; 326-33.
14. Wittsack HJ, Kugel H, Roth B., Heindel W. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease. J. Magn. Reson. Imaging 1996; 6: 889-93.
15. Kaul R, Casanova J, Johnson A.B., Tang P., Matalon R. Purification, characterization, and localization of aspartoacylase from bovine brain. J. Neurochem. 1991; 56: 129-35.
16. Feigenbaum A, Moore R, Clarke J et al. Canavan disease: Carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay. Am. J. Med. Genet. A 2004; 124A: 142-7.
17. Kaul R, Gao GP, Matalon R et al. Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Am. J. Hum. Genet. 1996; 59: 95-102.
18. Zeng BJ, Pastores GM, Leone P et al. Mutation analysis of the aspartoacylase gene in non-Jewish patients with Canavan disease. Adv. Exp. Med. Biol. 2006; 576: 165-73.
19. Glicksman S, Borgen C, Blackstein M et al. A thematic review of scientific and family interests in Canavan Disease: Where are the developmentalists? J. Intellect. Disabil. Res. 2013; 57: 815-25.
20. Hamaguchi H, Nihei K, Nakamoto N et al. A case of Canavan disease: The first biochemically proven case in a Japanese girl. Brain Dev. 1993; 15: 367-71.
21. Kobayashi K, Tsujino S, Ezoe T., Hamaguchi H, Nihei K, Sakuragawa N. Missense mutation (I143T) in a Japanese patient with Canavan disease. Hum. Mutat. 1998; Suppl. 1: S308-9.
22. Mizuguchi K, Hoshino H, Hamaguchi H., Kubota M. [Long term clinical course of Canavan disease - a rare Japanese case]. No To Hattatsu 2009; 41: 353-6.
23. Baslow MH, Hrabe J, Guilfoyle DN. Dynamic relationship between neurostimulation and N-acetylaspartate metabolism in the human visual cortex: Evidence that NAA functions as a molecular water pump during visual stimulation. J. Mol. Neurosci. 2007; 32: 235-45.
24. Wolf NI, Willemsen MA, Engelke UF et al. Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF. Neurology 2004; 62: 1503-8.
25. Kolodziejczyk K, Hamilton NB, Wade A, Karadottir R., Attwell D. The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes. Brain 2009; 132: 1496-508.
26. Baslow MH. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: A mechanistic explanation. J. Mol. Neurosci. 2003; 21: 185-90.
27. Tranberg M, Stridh MH, Guy Y et al. NMDA-receptor mediated efflux of N-acetylaspartate: Physiological and/or pathological importance? Neurochem. Int. 2004; 45: 1195-204.
28. Klugmann M, Leichtlein CB, Symes C.W., Serikawa T., Young D, During MJ. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Mol. Ther. 2005; 11: 745-53.
29. Clarner T, Wieczorek N, Krauspe B., Jansen K, Beyer C, Kipp M. Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model. J. Mol. Neurosci. 2014; 53: 22-30.
30. Bluml S. In vivo quantitation of cerebral metabolite concentrations using natural abundance 13C MRS at 1.5 T. J. Magn. Reson. 1999; 136: 219-25.
31. Kumar S, Mattan NS, de Vellis J. Canavan disease: A white matter disorder. Ment. Retard. Dev. Disabil. Res. Rev. 2006; 12: 157-65.
32. Madhavarao CN, Arun P, Moffett JR et al. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Proc. Natl Acad. Sci. U.S.A. 2005; 102: 5221-6.
33. Wang J, Leone P, Wu G et al. Myelin lipid abnormalities in the aspartoacylase-deficient tremor rat. Neurochem. Res. 2009; 34: 138-48.
34. Francis JS, Strande L, Markov V., Leone P. Aspartoacylase supports oxidative energy metabolism during myelination. J. Cereb. Blood Flow Metab. 2012; 32: 1725-36.
35. Liu J, Casaccia P. Epigenetic regulation of oligodendrocyte identity. Trends Neurosci. 2010; 33: 193-201.
36. Moffett JR, Namboodiri MA, Cangro C.B., Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991; 2: 131-4.
37. Bhakoo KK, Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: Implications for proton magnetic resonance spectroscopy signal in vivo. J. Neurochem. 2000; 74: 254-62.
38. Baslow MH, Suckow RF, Sapirstein V, Hungund BL. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes. J. Mol. Neurosci. 1999; 13: 47-53.
39. Bhakoo KK, Craig TJ, Styles P. Developmental and regional distribution of aspartoacylase in rat brain tissue. J. Neurochem. 2001; 79: 211-20.
40. Chakraborty G, Mekala P, Yahya D., Wu G, Ledeen RW. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: Evidence for myelin-associated aspartoacylase. J. Neurochem. 2001; 78: 736-45.
41. Mattan NS, Ghiani CA, Lloyd M et al. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination. Neurobiol. Dis. 2010; 40: 432-43.
42. Kumar S, Biancotti JC, Matalon R, de Vellis J. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease. J. Neurosci. Res. 2009; 87: 3415-27.
43. Janson CG, Assadi M, Francis J., Bilaniuk L, Shera D, Leone P. Lithium citrate for Canavan disease. Pediatr. Neurol. 2005; 33: 235-43.
44. Assadi M, Janson C, Wang DJ et al. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. Eur. J. Paediatr. Neurol. 2010; 14: 354-9.
45. Arun P, Madhavarao CN, Moffett JR et al. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease. J. Inherit. Metab. Dis. 2010; 33: 195-210.
46. Mathew R, Arun P, Madhavarao C.N., Moffett JR, Namboodiri MA. Progress toward acetate supplementation therapy for Canavan disease: Glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J. Pharmacol. Exp. Ther. 2005; 315: 297-303.
47. Segel R, Anikster Y, Zevin S et al. A safety trial of high dose glyceryl triacetate for Canavan disease. Mol. Genet. Metab. 2011; 103: 203-6.
48. Roe CR, Mochel F. Anaplerotic diet therapy in inherited metabolic disease: Therapeutic potential. J. Inherit. Metab. Dis. 2006; 29: 332-40.
49. Marin-Valencia I, Roe CR, Pascual JM. Pyruvate carboxylase deficiency: Mechanisms, mimics and anaplerosis. Mol. Genet. Metab. 2010; 101: 9-17.
50. Francis JS, Markov V, Leone P. Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease. J. Inherit. Metab. Dis. 2014; 37: 369-81.
51. Pederzolli CD, Rockenbach FJ, Zanin FR et al. Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats. Metab. Brain Dis. 2009; 24: 283-98.
52. Leone P, Shera D, McPhee SW et al. Long-term follow-up after gene therapy for Canavan disease. Sci. Transl. Med. 2012; 4: 165ra63.
53. Ahmed SS, Gao G. Gene therapy for Canavan's disease takes a step forward. Mol. Ther. 2013; 21: 505-6.